Skip to Main Content

Good morning, everyone, and welcome to another working week. Nice to see you again after we took an extended weekend respite. We hope your own break was refreshing and invigorating, because that predictable routine of meetings and deadlines and what-not has returned. The dog days of summer may still be here (our official mascots have confirmed this), but the world is still spinning. So the time has come to dig in. Here are some tidbits to help you along. Hope your day goes well and please do forward saucy information …

Gilead Sciences (GILD) will pay $11.9 billion to buy Kite Pharma (KITE) and its T-cell technology for harnessing the body’s own immune system to fight cancer, STAT tells us. Gilead has faced pressure from investors to make an acquisition and diversify its portfolio beyond its leading position in infectious-disease treatments and provide a new revenue as sales of its hepatitis C drugs decline, The Wall Street Journal notes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED